Literature DB >> 15995699

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.

Stephan Gasser1, Sandra Orsulic, Eric J Brown, David H Raulet.   

Abstract

Some stimulatory receptors of the innate immune system, such as the NKG2D receptor (also called KLRK1) expressed by natural killer cells and activated CD8(+)T cells, recognize self-molecules that are upregulated in diseased cells by poorly understood mechanisms. Here we show that mouse and human NKG2D ligands are upregulated in non-tumour cell lines by genotoxic stress and stalled DNA replication, conditions known to activate a major DNA damage checkpoint pathway initiated by ATM (ataxia telangiectasia, mutated) or ATR (ATM- and Rad3-related) protein kinases. Ligand upregulation was prevented by pharmacological or genetic inhibition of ATR, ATM or Chk1 (a downstream transducer kinase in the pathway). Furthermore, constitutive ligand expression by a tumour cell line was inhibited by targeting short interfering RNA to ATM, suggesting that ligand expression in established tumour cells, which often harbour genomic irregularities, may be due to chronic activation of the DNA damage response pathway. Thus, the DNA damage response, previously shown to arrest the cell cycle and enhance DNA repair functions, or to trigger apoptosis, may also participate in alerting the immune system to the presence of potentially dangerous cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995699      PMCID: PMC1352168          DOI: 10.1038/nature03884

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  28 in total

1.  Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance.

Authors:  Eric J Brown; David Baltimore
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

Review 2.  Roles of the NKG2D immunoreceptor and its ligands.

Authors:  David H Raulet
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

3.  GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation.

Authors:  Gabriela Hernández-Hoyos; Michele K Anderson; Chi Wang; Ellen V Rothenberg; Jose Alberola-Ila
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

Review 4.  The role of DNA breaks in genomic instability and tumorigenesis.

Authors:  Kevin D Mills; David O Ferguson; Frederick W Alt
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

Review 5.  Chk1 and Chk2 kinases in checkpoint control and cancer.

Authors:  Jiri Bartek; Jiri Lukas
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

6.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation.

Authors:  Christopher J Bakkenist; Michael B Kastan
Journal:  Nature       Date:  2003-01-30       Impact factor: 49.962

7.  Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1.

Authors:  Darren R Krause; Jyoti C Jonnalagadda; Magtouf H Gatei; Herman H W Sillje; Bin-Bing Zhou; Erich A Nigg; Kumkum Khanna
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

Review 8.  Genomic instability--the engine of tumorigenesis?

Authors:  Oliver M Sieber; Karl Heinimann; Ian P M Tomlinson
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

Review 9.  Mismatch repair and response to DNA-damaging antitumour therapies.

Authors:  M Bignami; I Casorelli; P Karran
Journal:  Eur J Cancer       Date:  2003-10       Impact factor: 9.162

10.  NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules.

Authors:  Melissa Lodoen; Kouetsu Ogasawara; Jessica A Hamerman; Hisashi Arase; Jeffrey P Houchins; Edward S Mocarski; Lewis L Lanier
Journal:  J Exp Med       Date:  2003-05-19       Impact factor: 14.307

View more
  538 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

2.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

3.  The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy.

Authors:  Jessica Strid; Olga Sobolev; Biljana Zafirova; Bojan Polic; Adrian Hayday
Journal:  Science       Date:  2011-12-02       Impact factor: 47.728

Review 4.  Effect of NKG2D ligand expression on host immune responses.

Authors:  Marine Champsaur; Lewis L Lanier
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

5.  NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation.

Authors:  Oliver Haworth; Manuela Cernadas; Bruce D Levy
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

6.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

7.  Yet another role for natural killer cells: cytotoxicity in immune regulation and viral persistence.

Authors:  Christine A Biron
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-31       Impact factor: 11.205

8.  NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

9.  Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus.

Authors:  Sílvia Vilarinho; Kouetsu Ogasawara; Stephen Nishimura; Lewis L Lanier; Jody L Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-08       Impact factor: 11.205

10.  NKG2D Ligands in Cancer Immunotherapy: Target or Not?

Authors:  Jennifer Wu
Journal:  Austin J Clin Immunol       Date:  2014-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.